We cannot guarantee that the content will display correctly while using Internet Explorer. To have the best browsing experience, please upgrade to Microsoft Edge, Google Chrome or Safari.

May 13, 2022

Sprint: DTx - Pharma Partnerships: Where Are We Heading To?

Commentary
HealthXL Team & HealthXL Community
&

The HealthXL Sprint 2-part meeting series connects senior leaders across our community to solve the latest health challenges. In our most recent sprint we discussed the current state of DTx-Pharma partnerships and what the future looks like. In this blog we’ve pulled out the top takeaways from this series. 

5 Key Recommendations: 

Digital Therapeutic (DTx) companions are a clear route for DTx-Pharma partnerships to begin: Partnerships between DTx companies and pharma may initially focus on DTx companions because they will generate evidence for the real world use to feed back into the drug discovery phase. DTx companies should recognise where they can add value to a pharmaceutical product or franchise. The position that pharma takes may depend on whether the DTx can support their go-to-market strategy or if it is a competitor. Pharma may have more appetite for companion type platforms that would help support their therapeutic areas and pharmaceuticals. A DTx solution that can help capture patient data, potentially reinforce the use and continuous prescribing of the pharmaceutical, and offer post treatment monitoring for drug reactivation may fit better into the current ecosystem. However, whilst a companion is a clear and obvious route, there’s value to both standalone and combination DTx products. For pharma, DTx partnerships can be a strategic way to diversify their portfolios.

Clinical evidence should go hand-in-hand with any Pharma-DTx partnership strategy: Clinical evidence is the nature of pharma business. DTx companies need to have more competencies to provide valid clinical evidence and be open to speaking the language of clinical trials and clinical outcomes if they are looking to engage with pharma. If necessary, some pharma companies  may support DTx companies in gaining evidence if they have the courage to try to create it and fail. Clinical evidence is only going to become more important as the market becomes more saturated. Digital products improve dynamically after they reach the market, providing an opportunity to collect real world evidence to support updates and product improvements across its lifespan. This reinforces the importance of DTx companies having competencies in discussing clinical evidence. 

Seek a mentor to navigate the pharma organization: DTx companies have insight into the concept of a digital relationship to people with disease. This insight is underrepresented to some of the stakeholders in pharma. Day-to-day budget holders and decision makers in organizations may be separate from the conversation or may not always be able to see the long term value proposition of DTx, even if there’s senior management support. This brings up challenges for accessing the right gateway within the organization. There is an opportunity for DTx companies to seek a mentor as an executive sponsor and digital health advocate to help navigate the organization.

Adoption of a DTx by the Healthcare Providers (HCPs) is important: Engaging HCPs needs to be strongly prioritized if the parma-DTx partnership is to be successful. Whether the DTx route to market is direct to consumer (D2C) or via a Provider, and even if the DTx is reimbursed and has a framework prepared, there needs to be a strategy in place to encourage  HCPs to change their habits before they prescribe, recommend or use the DTx. A balance between cost and revenue of the DTx might be agreed upon at pharma management level. However, this does not always prove resilient when attempting to get HCPs to adopt the solution. Simplistically, in order to engage HCPs, a minimal friction environment platform must be created and clinical outcomes from the DTx should be available in the HCP’s electronic health record (EHR). However, HCPs are only one of the key stakeholders. Engagement of patients and users will also be a key component of success.

Timing is everything: Pharma companies are still at an early stage in their understanding of DTx, but are reticent about the use of DTx upstream in the development cycle. Digital health teams in pharma are asked to bring in DTx much later in the process, but it is not enough to approach DTx as a case finding tool when drug exclusivity runs out. Pharma teams on the commercial side and teams on the clinical trials side need to engage more to get DTx incorporated earlier in the pharmaceutical stage to span R&D, clinical trials and commercial thinking. 

Future Gazing

DTx-Pharma partnerships are nascent and the strategy is only starting to become well defined. These partnerships need to be more patient-focused and business oriented. The patient's needs must always come first and the ideal partnership will drive better outcomes by promoting the intervention without negatively affecting drug sales.

DTx platforms need to be interoperable and easy to use. Rather than numerous point solutions, HCPs need a simple solution that fits into their current workflow. Solutions that address common comorbidities may be easier to adopt and more likely to gain tracking with HCPs.  If this approach fails in the short-term, platforms that address general symptoms across multiple therapeutic areas may find more success with HCPs. 

Experts included:  Bernhard Kappe (Founder & CEO, Orthogonal), Daphne Petrich (Senior Business Development Manager, HelloBetter), Deepti Warad (Senior Clinical Trial Physician, BMS), Joseph Rubinsztain (CEO, ChronWell), Karine Soulat (Marketing Consultant on health and ehealth, Ke-Health), Katie Cannon (Head of Growth, Avegen), Kevin Darcy (Director, Link Strategy, Veeva Systems), Laura Carlin (Head of Strategic Alliances, ieso), Matt Norton (VP of Marketing & Commercial Development, S3 Connected Health) Michael Heupel (Head of Pharma & MedTech, Flying Health), Omri Shor (Founder & CEO, Medisafe), Quake Pletcher (Sr. Director, Digital Health Partnership Management, Eli Lilly and Company), Vasyl Pyrozhyk (VP Healthcare, Sumitomo Mitsui Banking Corporation), and Aislinn Mc Phillips (Digital Health Analyst, HealthXL).

*All opinions are the participants’ own and do not necessarily reflect the stance of their respective employers.

We can provide an introduction on your behalf so that you can contact them directly with any questions/queries on this topic. Simply click on the link below to request an introduction.

We can provide an introduction on your behalf so that you can contact them directly with any questions/queries on this topic. Simply click on the link below to request an introduction.

Request an Introduction

We can provide an introduction on your behalf so that you can contact them directly with any questions/queries on this topic. Simply click on the link below to request an introduction.

Request an Introduction

Ready to read more? HealthXL members can access the full peak of the report on the HealthXL Community Hub.

Not yet a member of HealthXL? Download your 11 page snapshot of the report.

Download your 11 page snapshot

Connect with peers and share insights

Don't miss out on the discussion of the latest insights and reports on digital health. Meet with peers and take a deep dive for 75 minutes. Unlike at webinars, you can freely exchange experiences and insights to solve challenges and design the future of DTx.

Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

Masterclass: DTx Reimbursement in the US - PBMs as Coverage Scale Catalysts

10th August @ 10:45AM EDT

Are you a DTx or Pharma company seeking wide-spread reimbursement of a DTx product in the US? Join this Masterclass led by Mike Pace to learn more about this topic and share your experiences with others working in this space.

Featuring
Michael Pace
Michael Pace
CEO & Founder at PalmHealth.co
Featuring
Michael Pace
Michael Pace
CEO & Founder at PalmHealth.co
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

Masterclass: Value, Cost and Pricing in Regulated Digital Health Solutions

11th August @ 10:45AM EDT

Digital Health solutions are top of mind for biopharma companies in 2022, and Software as Medical Device (SaMD) is a crucial cornerstone for top-tier companies. Join this Masterclass led by BrightInsight to dive deeper into this topic and discuss this further with your peers working in this space.

Featuring
David Matthews, PhD
David Matthews, PhD
CCO, BrightInsight
Featuring
David Matthews, PhD
David Matthews, PhD
CCO, BrightInsight
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

Sustainable Business Models for DTx

16th August @ 10:45AM EDT

It is one of the key questions that every digital therapeutic (DTx) company must answer - what business model will set them up for success in the long run? Join this meeting to discuss this further and share your experiences with your peers working in this space.

Featuring
Elena Mustatea
Elena Mustatea
CEO, Bold Health
Rick Bartels
Rick Bartels
Managing Partner , DTxCC
Featuring
Elena Mustatea
Elena Mustatea
CEO, Bold Health
Rick Bartels
Rick Bartels
Managing Partner , DTxCC
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

Payers Partnerships for DTx

17th August @ 10:45AM EDT

Digital Therapeutics (DTx) vendors face many challenges on their journey to commercialization, such as generating clinical data, health economics evidence and achieving regulatory status. Join this meeting to discuss this topic further and share your experiences with others working in this space.

Featuring
Elena Mustatea
Elena Mustatea
CEO, Bold Health
Kevin Darcy
Kevin Darcy
Director, Link Strategy at Veeva Systems
Featuring
Elena Mustatea
Elena Mustatea
CEO, Bold Health
Kevin Darcy
Kevin Darcy
Director, Link Strategy at Veeva Systems

Are you a HealthXL Member? See the Full Report Here

Non-HealthXL Member? You can purchase the report HERE

HealthXL Digital Health Meetings

Want to join the discussion now?

Join our Digital Health Meetings and take a deep dive for 75 minutes into topics like digital therapeutics, patient support, telehealth, clinical trials, dermatology and many more. These Meetings are not regular webinars: No audience, no recording and no hiding behind a screen. You actively participate in a discussion to solve your present challenges and design the future of digital health. And with a free account on our Community Hub, you stay connected and up-to-date on the latest news and insights, allowing you to fully immerse yourself in the topic before, during and after.

Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

Masterclass: DTx Reimbursement in the US - PBMs as Coverage Scale Catalysts

10th August @ 10:45AM EDT

Are you a DTx or Pharma company seeking wide-spread reimbursement of a DTx product in the US? Join this Masterclass led by Mike Pace to learn more about this topic and share your experiences with others working in this space.

Featuring
Michael Pace
Michael Pace
CEO & Founder at PalmHealth.co
Featuring
Michael Pace
Michael Pace
CEO & Founder at PalmHealth.co
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

Masterclass: Value, Cost and Pricing in Regulated Digital Health Solutions

11th August @ 10:45AM EDT

Digital Health solutions are top of mind for biopharma companies in 2022, and Software as Medical Device (SaMD) is a crucial cornerstone for top-tier companies. Join this Masterclass led by BrightInsight to dive deeper into this topic and discuss this further with your peers working in this space.

Featuring
David Matthews, PhD
David Matthews, PhD
CCO, BrightInsight
Featuring
David Matthews, PhD
David Matthews, PhD
CCO, BrightInsight

Executive 1-2-1 with the HealthXL Digital Health Community

15th August @11AM EDT

Do you want to network with other innovators and leaders in digital health? Are you looking to identify potential partners? Join us for the new HealthXL style of virtual speed networking and meet other members working in this space!

Featuring
Aahuti Rai
Aahuti Rai
Strategic Advisor, Healthcare Innovation at Four Points Consulting Ltd
Chris Wasden
Chris Wasden
Head of Pharma Speciality Solutions & Corporate Strategy, Twill
Featuring
Aahuti Rai
Aahuti Rai
Strategic Advisor, Healthcare Innovation at Four Points Consulting Ltd
Chris Wasden
Chris Wasden
Head of Pharma Speciality Solutions & Corporate Strategy, Twill
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

Sustainable Business Models for DTx

16th August @ 10:45AM EDT

It is one of the key questions that every digital therapeutic (DTx) company must answer - what business model will set them up for success in the long run? Join this meeting to discuss this further and share your experiences with your peers working in this space.

Featuring
Elena Mustatea
Elena Mustatea
CEO, Bold Health
Rick Bartels
Rick Bartels
Managing Partner , DTxCC
Featuring
Elena Mustatea
Elena Mustatea
CEO, Bold Health
Rick Bartels
Rick Bartels
Managing Partner , DTxCC

What’s a Rich Text element?

The rich text element allows you to create and format headings, paragraphs, blockquotes, images, and video all in one place instead of having to add and format them individually. Just double-click and easily create content.

Static and dynamic content editing

A rich text element can be used with static or dynamic content. For static content, just drop it into any page and begin editing. For dynamic content, add a rich text field to any collection and then connect a rich text element to that field in the settings panel. Voila!

How to customize formatting for each rich text

Headings, paragraphs, blockquotes, figures, images, and figure captions can all be styled after a class is added to the rich text element using the "When inside of" nested selector system.

We cannot guarantee that the content will display correctly while using Internet Explorer. To have the best browsing experience, please upgrade to Microsoft Edge, Google Chrome or Safari.